Prot #A18-15331: A Phase III Multicenter, Randomized, Open Label Study of APR-246 in Combination with Azacitidine Versus Azacitidine Alone for the Treatment of TP53 Mutant Myelodysplastic Syndromes

Project: Research project

StatusActive
Effective start/end date9/26/199/26/22

Funding

  • Theradex (Prot #A18-15331)
  • Aprea Therapeutics AB (Prot #A18-15331)